Purpose: The increase of serum activity of gamma-glutamyltranferase (gammaGT) through the action of enzyme-inducing anticonvulsant drugs has been widely documented; however, the behaviour of its multiple forms and its relationship with the degree of enzyme induction has received little coverage. This subject is the major aim of our paper.
Methods: An electrophoretic study of the serum gammaGT isoforms was made in 90 adult epileptic patients under chronic treatment with phenobarbital, phenytoin and carbamazepine in polytherapy.
Results: A significant correlation was found (p<0.001) between the drug score and urinary excretion of D-glucaric acid (DGA) (r=0.773), total gammaGT (r=0.382), gammaGT1 (r=0.398) and gammaGT2 (r=0.361). In a group of 11 patients with the gammaGT3 isoforms, considered a sensitive test for cholestasis, serum activities of total gammaGT, gammaGT1, gammaGT2 and 5 -nucleotidase were found that were significantly higher than in the 79 patients without the gammaGT3 isoform (p<0.001); however, for the drug score and excretion of DGA, no significant differences were found, suggesting a similar degree of enzyme induction in both groups of patients.
Conclusions: The presence of cholestasis, at least biochemically detectable in some of these patients, appears to be a factor of paramount importance when interpreting the effect of enzyme-inducing anticonvulsant drugs on serum gammaGT. This fact may contribute towards explaining its highly varied response to the administration of these drugs.
Download full-text PDF |
Source |
---|
Ther Adv Rare Dis
January 2025
SynGAP Research Fund, 2856 Curie Pl., San Diego, CA 92122, USA.
-related disorder (SRD) is a developmental and epileptic encephalopathy caused by a disruption of the gene. At the beginning of 2024, it is one of many rare monogenic brain disorders without disease-modifying treatments, but that is changing. This article chronicles the last 5 years, beginning when treatments for SRD were not publicly in development, to the start of 2024 when many SRD-specific treatments are advancing.
View Article and Find Full Text PDFFront Neurol
December 2024
Brain and Development Research Axis, Azrieli CHU Ste-Justine Research Center, Montreal, QC, Canada.
Epileptic spasms (ES) are a unique seizure type typically presenting in the form of infantile epileptic spasms syndrome (IESS) with characteristic hypsarrhythmia on scalp EEG and a preponderance with developmental delay or regression. While pharmacotherapy is the mainstay of treatment, surgical options, including disconnective or resective procedures, are increasingly recognized as viable therapeutic options for recurrent or persistent ES. However, limited data on safety, effectiveness, and prognostic factors hinder informed decision-making regarding surgery indications, timing, and intervention type.
View Article and Find Full Text PDFiScience
January 2025
Vivian L. Smith Department of Neurosurgery, McGovern Medical School at UT Health Houston, Houston, TX 77030, United States of America.
Speech production engages a distributed network of cortical and subcortical brain regions. The supplementary motor area (SMA) has long been thought to be a key hub in coordinating across these regions to initiate voluntary movements, including speech. We analyzed direct intracranial recordings from 115 patients with epilepsy as they articulated a single word in a subset of trials from a picture-naming task.
View Article and Find Full Text PDFMed Chem
January 2025
São Paulo State University - UNESP, School of Pharmaceutical Sciences, Araraquara, São Paulo, Brazil.
Introduction: Epilepsy encompasses numerous syndromes characterized by spontaneous, intermittent, and abnormal electrical activity in the brain. Affecting about 1-2% of the population, it is estimated that approximately 30-40% of patients experience refractory epilepsy, which does not respond to traditional anticonvulsant drugs.
Aims: Therefore, developing novel, safe, and effective antiepileptic drugs remains a medical need.
BMJ Open
December 2024
INSERM UMR1231 Génétique des Anomalies du Développement (GAD), Université de Bourgogne, Dijon, France.
Introduction: The megalencephaly capillary malformation polymicrogyria (MCAP syndrome) results from mosaic gain-of-function variants. The main clinical features are macrocephaly, somatic overgrowth, neurodevelopmental delay and brain anomalies. Alpelisib (Vijoice) is a recently FDA-approved PI3Kα-specific inhibitor for patients with PIK3CA-related overgrowth spectrum (PROS).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!